DE HEYDER KOEN,SCHU PETER,SERANTONI MICHELLE,VAN OPSTAL OMER
申请号：
SK500322012
公开号：
SK288079B6
申请日:
2001.08.07
申请国别(地区):
SK
年份:
2013
代理人:
摘要：
A method comprising expressing the hepatitis B surface antigen (HBsAg) as a recombinant protein in Saccharomyces cerevisiae, processing the yeast cells to provide a crude antigen preparation, subjecting the crude antigen preparation to gel permeation chromatography, wherein the used elution buffer does not contain thiomersal, subjecting the antigen-containing eluant from step (c) to ion exchange chromatography, adding cysteine to the antigen-containing eluant pool obtained after previous step, subjecting the preparation from previous step to caesium chloride ultracentrifugation and combining the purified HBsAg with a pharmaceutically acceptable excipient to produce a stable, immunogenic hepatitis B vaccine, wherein no thiomersal id added to the resulting vaccine.A method comprising expressing the hepatitis B surface antigen (HBsAg) as a recombinant protein in Saccharomyces cerevisiae, processing the yeast cells to provide a crude antigen preparation, subjecting the crude antigen preparation to gel permeation chromatography, wherein the used elution buffer does not contain thiomersal, subjecting the antigen-containing eluant from step (c) to ion exchange chromatography, adding cysteine to the antigen-containing eluant pool obtained after previous step, subjecting the preparation from previous step to caesium chloride ultracentrifugation and combining the purified HBsAg with a pharmaceutically acceptable excipient to produce a stable, immunogenic hepatitis B vaccine, wherein no thiomersal id added to the resulting vaccine.
